In This Article:
Bolt Biotherapeutics (NASDAQ:BOLT) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$1.14m (down 55% from 3Q 2023).
-
Net loss: US$15.2m (loss narrowed by 6.6% from 3Q 2023).
-
US$0.40 loss per share (improved from US$0.43 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bolt Biotherapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) also missed analyst estimates by 13%.
Looking ahead, revenue is expected to decline by 76% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 22%.
Performance of the American Biotechs industry.
The company's shares are down 4.4% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Bolt Biotherapeutics (1 is a bit unpleasant!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.